Bristol Myers Squibb and MassBio Event Poised to Catalyze Scientific Innovation

Aug 02, 2022

Bristol Myers Squibb Pharma Day® to welcome innovators and biotech companies on October 6

On October 6, Bristol Myers Squibb (BMS) will team up with MassBio to host a Pharma Day®, during which the global biopharma will showcase its R&D strategy and directly connect with potential collaborators across the life sciences innovation ecosystem.

Innovators with drug candidates focusing on cardiovascular, oncology, hematology, immunology, and neuroscience – as well innovators with cross-therapeutic platforms and digital health technologies – who are actively looking for collaboration opportunities are encouraged to apply for one-on-one meetings with BMS representatives by August 26, 2022 at midnight. For more details on BMS areas of interest for R&D collaboration, please visit the MassBio website.

“As a company focused on transforming patients’ lives through science, Bristol Myers Squibb is collaborating at the center of the biotech ecosystem to accelerate breakthrough innovation for patients. Enabled by our differentiated partnering approach and focus on best and first-in-class medicines to treat the most serious diseases, external innovation that builds upon our strong internal R&D continues to be core to our innovation strategy. We look forward to forming new relationships with emerging innovators, deepening our collaborations in the most vibrant scientific hubs like Massachusetts, and discovering new ways to address the unmet needs of patients,” says Jie D’Elia, Senior Vice President, Business Development, Oncology, Hematology, Cell Therapy, Bristol Myers Squibb.

“Now more than ever, we need to make the connections that empower small and emerging biotechs to go big on their science and take on the most difficult challenges facing patients worldwide,” says MassBio CEO Joe Boncore. “MassBio’s Pharma Days provide a platform for large and established companies to access and collaborate with the visionaries who are spearheading revolutionary research, and we look forward to seeing what comes out of this partnership with Bristol Myers Squibb.”

Following the one-on-one meetings on October 6, BMS will host an in-person open information session and networking reception at the MassBioHub starting at 2:30PM. This event will focus on BMS’ collaboration capabilities, platforms, and expertise. To register for this event, please visit the MassBio website.

“Our partnering initiatives facilitate the connections that empower the entire ecosystem to drive innovation forward,” adds Kendalle Burlin O’Connell, President & COO, MassBio. “By putting biopharma powerhouses like Bristol Myers Squibb in a position to share their goals and strategies with early-stage institutions that are potentially outside their professional spheres through Pharma Day’s one-on-one meetings and networking events, MassBio builds the relationships that can address the world’s unmet medical needs.”

MassBio’s Pharma Days® provide unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. Since 2010, MassBio has facilitated more than 1,000 connections between emerging entrepreneurs and established biopharmaceutical companies through Pharma Days® and other partnering initiatives.

See all MassBio News